StockGuide AI - assistant for market research

Novo Nordisk Files Lawsuit Against Eli Lilly Over Misleading Advertising for GLP-1 Drugs

07/21/2026, 05:37 AM business announcement pharma

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that Lilly's advertising misrepresents the efficacy of its diabetes and obesity drugs compared to Novo's products. This legal action highlights the competitive tensions in the GLP-1 drug market, particularly as Novo seeks to regain market share with its new high-dose Wegovy injection.

Analysts HSBC downgraded AstraZeneca (AZN) from Buy to Hold, citing a challenging outlook and reduced target price to £137.50

07/14/2026, 06:36 AM rating_drop Analysts: analysts, HSBC pharma

HSBC has downgraded its rating for AstraZeneca from buy to hold, citing concerns over the company's future following a recent clinical trial failure that negatively impacted its stock price.

AstraZeneca’s Failed Wainua Trial Raises Concerns Over Pipeline Valuation Premium

07/10/2026, 10:30 PM business review pharma

AstraZeneca's recent failure in a late-stage trial for its drug Wainua has raised concerns about the company's overall pipeline valuation, despite analysts estimating only a modest financial impact. The market's reaction suggests a reassessment of investor confidence in AstraZeneca's ability to deliver successful drug developments.

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

06/09/2026, 12:32 AM growth pharma space

The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.

Analysts expect Johnson & Johnson (JNJ) to show potential for breakout following Eli Lilly’s (LLY) recent all-time highs

06/08/2026, 11:35 AM investing forecast Analysts: analysts pharma healthcare

Pharmaceutical stocks are gaining momentum, with Eli Lilly leading the charge and reaching all-time highs, indicating a potential for broader sector strength that could benefit other major companies like Johnson & Johnson.

Stocks to Watch: AutoZone Declines on Sales Challenges, Eli Lilly Acquires Three Companies, Ferrari Launches Electric Vehicle, and Lear Upgraded by TD Cowen

05/26/2026, 05:34 AM business review auto pharma

Several companies are experiencing notable stock movements ahead of the market opening, with AutoZone facing declines due to disappointing international sales, while Eli Lilly's acquisition strategy boosts its stock.